Breast Cancer
-
VERITAC-2: Vepdegestrant Demonstrates Clinical Benefit in ESR1-Mutated, ER+/HER2- Advanced Breast Cancer After Endocrine Therapy
Arvinas’ VERITAC-2 trial data, presented at ESMO 2025, showed vepdegestrant significantly delayed deterioration in quality of life, pain, and functionality compared to fulvestrant in ESR1-mutated ER+/HER2- advanced breast cancer patients. The trial enrolled 624 patients, with 270 harboring ESR1 mutations. Progression-free survival improved statistically, and the market awaits overall survival data, the key secondary endpoint. Vepdegestrant is a PROTAC ER degrader being co-developed with Pfizer and has received FDA Fast Track designation.
-
Giredestrant Improves Progression-Free Survival in ER-Positive Advanced Breast Cancer: Roche’s Phase III evERA Trial
Roche’s Phase III evERA trial showed promising results for giredestrant plus everolimus in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor therapy. The combination significantly improved progression-free survival (PFS) compared to standard endocrine therapy plus everolimus. The PFS risk reduction was 44% in ITT and 62% in ESR1-mutated patients. While overall survival data is still maturing, a positive trend was observed. Giredestrant + everolimus could become a new standard of care.
-
Genentech’s Itovebi Extends Survival in HR-Positive Advanced Breast Cancer, New Data Reveal
Genentech announced positive overall survival data from the Phase III INAVO120 study, showing that the Itovebi regimen reduced death risk by over 30% in advanced breast cancer patients with PIK3CA mutations. Compared to palbociclib and fulvestrant alone, this Itovebi combination with palbociclib and fulvestrant significantly improved overall survival. The findings will be presented at the 2025 ASCO meeting.
